The localized nature of the LaZure treatment modality, its inherent preference for cancer cells, and the absence of treatment-related side effects, combine to give the LDAC technology significant advantages in treating a variety of cancer types.

The LDAC investigational clinical device is a minimally invasive system that uses low-intensity electric fields to preferentially destroy tumors. The system can produce a modest increase in tumor tissue temperature — below the threshold required to induce the protein coagulation associated with thermal ablation — with minimal observed damage to healthy tissue both within and surrounding the treatment field.

LaZure’s mission is to continue development of its proprietary technology, allowing for the effective treatment of a variety of solid cancer types while minimizing or eliminating the serious treatment-related side effects that are often associated with currently available cancer therapies.